Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients. Intersect ENTâs initial focus is on improving the treatment of chronic sinusitis, an inflammatory condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain. Chronic sinusitis often requires a complex combination of medical and surgical therapy and is hence one of the most costly conditions to U.S. employers. While traditional surgical solutions relieve symptoms in many patients, disease recurrence is frequent with the majority of patients experiencing recurrent symptoms within the first year. Intersect ENT is a publicly traded company. Source
No articles found.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrate...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a Sa...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
NowKeto wants to empower people to live the ketogenic lifestyle through their diet...
NowKeto wants to empower people to live the ket...
As the leader womenâs health, we deliver life-changing and life-saving diagnosti...
As the leader womenâs health, we deliver life...
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company d...
Beyond Air Inc. is a clinical-stage medical dev...
Histogenics historically focused on the development of restorative cell therapies,...
Histogenics historically focused on the develop...
Lianluo Smart Limited is a professional smart service products provider, which dev...
Lianluo Smart Limited is a professional smart s...
Join the National Investor Network and get the latest information with your interests in mind.